Rheumatoid Arthritis Clinical Trials
Here are the 6 most popular medical studies for rheumatoid arthritis
Shared Decision Making Intervention for Rheumatoid Arthritis
This trial will test whether a shared decision making intervention can help reduce disease activity, improve medication adherence, and increase patient knowledge about RA in Veterans Affairs (VA) patients with RA.
Biological DMARD
Anti-TNFα continued perioperatively for Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a frequent inflammatory arthritis that can lead to severe joint deformity and often requires orthopaedic surgical interventions. Anti-Tumor Necrosis Factor α (anti-TNFα) are biological disease-modifying antirheumatic drugs (DMARDs) increasingly used in the treatment of rheumatoid arthritis. An increased risk of opportunistic infection was demonstrated in patients treated with those drugs. This observation led many national committees to recommend anti-TNFα suspension in the perioperative period to avoid a raise in the postoperative infection risk in those patients. This approach is not supported by the data available in the current literature and it exposes patients to an increased risk of inflammatory flare ups of their disease during and after anti-TNFα suspension, which can compromise their postoperative rehabilitation and their quality of life. The objective of this prospective randomized multicentric trial is to determine the effect of anti-TNFα suspension in the perioperative period on the postoperative infection risk. Overall, 660 rheumatoid arthritis patients requiring an elective foot or ankle surgery will be randomized into two groups. In the first group, anti-TNFα will be stopped 3 half-lives before the surgery while they will be continued in the second group. The postoperative infection rate will be compared between the two groups. Postoperative complication rates, flares and revision surgeries as well as the functional improvement will be compared. The study hypothesis is that there is no significant difference in the risk of postoperative infection between the two groups. Results from this study will help determine the optimal way to use anti-TNFα in the perioperative period and will therefore improve the quality of life of rheumatoid arthritis patients.
TNF Inhibitor
Adalimumab +2 More for Rheumatoid Arthritis
This trial is testing whether people in remission from RA can stay in remission after discontinuing use of a TNF inhibitor drug, and whether clinical, imaging and immunological measurements can help predict which patients will flare after discontinuing the drug.
Partners for Rheumatoid Arthritis
The goal of PARASS is to develop a network of increased social support for Rheumatoid Arthritis (RA) patients that will improve patient outcomes and further promote understanding of RA among physicians and patients in the clinic community. This will be accomplished with the development and implementation of Buddy pairing and one -on- one informational support to be called Patient-to-Patient Connection.
MRC375 for Rheumatoid Arthritis
This study will treat moderate to severe rheumatoid arthritis with MRC375 (either 75 mg 3 times a day, 150 mg 3 times a day or placebo 3 times a day)in patients 18 years of age or older that can be currently on low doses of methotrexate or can stop treatment of current RA medications to enter the study. Safety of MRC375 will also be evaluated. There are up to 8 clinic visits over 24 weeks.
Popular filter options for rheumatoid arthritis trials
RA Clinical Trials
View 85 RA medical studies.
Behavioral Intervention
Mindfulness Program for Rheumatoid Arthritis
This trial will test a mindfulness program in individuals with rheumatoid arthritis (RA). The goals are to assess patient satisfaction, identify barriers to participation, and understand how mindfulness impacts RA symptoms. Participants will
Tumor Necrosis Factor (TNF) Blocker
Enbrel with Sofusa DoseConnect for Rheumatoid Arthritis
This trial is testing a new way of giving Enbrel to people with RA. All patients will start with a low dose of Enbrel, and if it's well tolerated, the dose will be increased.
Osteoarthritis Clinical Trials
View 16 Osteoarthritis medical studies.
Vitamin
Vitamin D + Fish Oil for Health Improvement
This trial is studying whether taking daily dietary supplements of vitamin D3 or omega-3 fatty acids reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses.
Orthopedic Implant
Actis Total Hip System for Hip Replacement
This trial looked at the outcomes of using the Actis Total Hip System in cementless primary THA and hemi-hip arthroplasty procedures. Clinical, radiographic, and device and procedure related adverse event assessments were used to evaluate the performance of the system.
Phase 3 Rheumatoid Arthritis Clinical Trials
View 88 phase 3 rheumatoid arthritis medical studies.
Marine and Botanical Oils
combination fish oil and borage seed oil +2 More for Rheumatoid Arthritis
The object of this study is to determine whether treatment of rheumatoid arthritis (RA) with a combination of fish oil and borage seed oil is superior to treatment with either oil alone. This study will also investigate the biochemical, immunological, and molecular mechanism responsible for the therapeutic effects of these fatty acids. Each patient will be followed for eighteen months.
Disease-modifying antirheumatic drugs (DMARDs)
DMARDs for Rheumatoid Arthritis
This trial is testing whether a certain type of arthritis medication can help predict clinical responses to other types of arthritis medication. All patients will receive a starting dose of the medication being tested, which may be adjusted by the investigator as needed. If a subject becomes intolerant to the medication being tested, the subject will be withdrawn from the study. Data from the study will be collected at the end of the trial.
Janus Kinase (JAK) Inhibitor
Long-Term Safety of Filgotinib for Rheumatoid Arthritis
This trial will study the long-term safety of the drug filgotinib in people who have completed other trials testing the drug's effectiveness in treating rheumatoid arthritis.
Rheumatoid Arthritis Clinical Trials With No Placebo
View 88 rheumatoid arthritis medical studies that do not have a placebo group.
Behavioral Intervention
Mindfulness Program for Rheumatoid Arthritis
This trial will test a mindfulness program in individuals with rheumatoid arthritis (RA). The goals are to assess patient satisfaction, identify barriers to participation, and understand how mindfulness impacts RA symptoms. Participants will
Tumor Necrosis Factor (TNF) Blocker
Enbrel with Sofusa DoseConnect for Rheumatoid Arthritis
This trial is testing a new way of giving Enbrel to people with RA. All patients will start with a low dose of Enbrel, and if it's well tolerated, the dose will be increased.
Behavioral Intervention
Multidisciplinary Care for Rheumatoid Arthritis
This trial will test a new intervention for socioeconomically disadvantaged Hispanic adults with rheumatoid arthritis to see if it improves remission rates. The intervention is based on a partnership between the patient and the extended healthcare team, and includes things like self-management education and technology-based at-home monitoring of symptoms.
View More Rheumatoid Arthritis Trials
See another 56 medical studies focused on rheumatoid arthritis.
Frequently Asked Questions
Introduction to rheumatoid arthritis
What are the top hospitals conducting rheumatoid arthritis research?
When it comes to advancing treatments for rheumatoid arthritis, several hospitals are leading the charge. One such institution is the Altoona Center for Clinical Research in Duncansville, which currently has eight active clinical trials dedicated to this condition and an impressive history of 64 completed trials since their first recorded trial in 2002. In Boston, Brigham and Women's Hospital is making significant strides as well with five ongoing rheumatoid arthritis trials and a total of 21 previously conducted studies dating back to their inaugural trial in 2003. Meanwhile, Desert Medical Advances in Palm Desert contributes its expertise with four active clinical trials and a commendable track record of 33 previous investigations since their initial rheumatoid arthritis trial was documented in 2005.
Additionally, Altoona Center For Clinical Research continues its dedication by conducting four current clinical tests while having accomplished twenty-five researches over years including multiple facets from inception phase itself during that very year they started examining Rheumatoid Arthritis patients.For Physician Research Collaboration LLC located at Lincoln , offering treatment possibilities through participating into their four on-going RA medical examinations;their initiatives so far go back till they registered commencement initiative around fourteen years ago from present time i.e.,in year2007.
These establishments represent the hope and determination found within the medical community when it comes to combating rheumatoid arthritis. By conducting these vital clinical trials, researchers aim not only to alleviate symptoms but also develop groundbreaking therapies that can improve the lives of millions affected by this chronic autoimmune disease worldwide
Which are the best cities for rheumatoid arthritis clinical trials?
When it comes to rheumatoid arthritis clinical trials, several cities are at the forefront of research and development. Houston, Texas leads with 23 active trials focusing on treatments like Baricitinib, Upadacitinib, and Peresolimab. Duncansville, Pennsylvania follows closely behind with 17 ongoing studies investigating options such as KPL-404 and Abatacept. Lastly, Boston, Massachusetts also has 17 active trials exploring interventions including Cohort B and Arm B2P: BNT162b2 along with Nivolumab. These cities offer individuals with rheumatoid arthritis access to cutting-edge clinical trials that open doors for potential breakthroughs in treatment options and improved quality of life.
Which are the top treatments for rheumatoid arthritis being explored in clinical trials?
Exciting developments in rheumatoid arthritis research are underway, with several promising treatments taking center stage in clinical trials. Leading the pack is upadacitinib, currently being explored in two active trials and boasting a total of 15 past studies dedicated to rheumatoid arthritis since its introduction in 2014. Close behind is abatacept, which has caught the attention of researchers with two ongoing trials and an impressive record of 54 all-time clinical trials for this condition since its listing back in 2002. Also making waves is baricitinib, involved in two current investigations and contributing to a cumulative total of 13 previous rheumatoid arthritis studies since its debut in 2007. As these trials progress, new possibilities for treating rheumatoid arthritis may soon become reality.
What are the most recent clinical trials for rheumatoid arthritis?
Exciting developments are underway in the field of rheumatoid arthritis, with several recent clinical trials bringing hope for improved treatment options. One such trial involves VIB4920 in combination with TNFi, showing promise in its Phase 2 study that commenced on September 15th, 2023. Additionally, ANB030 SC Dose 1 and Certolizumab + Nipocalimab have shown potential benefits as well during their respective Phase 2 trials which began on August 31st and August 15th, respectively. Another notable advancement is Upadacitinib's ongoing Phase 3 trial initiated on June 15th, aiming to further validate its efficacy against this debilitating condition. Lastly, LY3871801 has entered a Phase-2a study since May 23rd to investigate its potential benefits for individuals living with rheumatoid arthritis. These promising clinical trials pave the way towards new possibilities of managing and treating this chronic inflammatory disease effectively.
What rheumatoid arthritis clinical trials were recently completed?
Several recent clinical trials have brought significant advancements in the treatment of rheumatoid arthritis. In October 2021, Janssen Research & Development completed two trials for potential therapies: JNJ-67484703 and Nipocalimab. Furthermore, UCB Biopharma SRL wrapped up their Certolizumab pegol trial in February 2021. Other noteworthy completed trials include LY3462817 by Eli Lilly and Company in January 2021, PF-06650833 by Pfizer in July 2020, and branebrutinib sponsored by Bristol-Myers Squibb in January 2020. These studies demonstrate the ongoing efforts to find new therapeutic options for individuals living with rheumatoid arthritis, highlighting a promising future for patients grappling with this challenging condition.